Cargando…
Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations
BACKGROUND: Uncontrolled hyperphosphatemia in chronic kidney disease (CKD) patients commonly results in vascular calcification leading to increased risk of cardiovascular disease. Phosphate binders (PBs) are used for hyperphosphatemia and can be calcium-based (CBPBs) or non-calcium-based (NCBPBs), t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166732/ https://www.ncbi.nlm.nih.gov/pubmed/33677736 http://dx.doi.org/10.1007/s10198-021-01275-3 |
_version_ | 1783701557428092928 |
---|---|
author | Chaiyakittisopon, Kamolpat Pattanaprateep, Oraluck Ruenroengbun, Narisa Sapankaew, Tunlanut Ingsathit, Atiporn Mckay, Gareth J. Attia, John Thakkinstian, Ammarin |
author_facet | Chaiyakittisopon, Kamolpat Pattanaprateep, Oraluck Ruenroengbun, Narisa Sapankaew, Tunlanut Ingsathit, Atiporn Mckay, Gareth J. Attia, John Thakkinstian, Ammarin |
author_sort | Chaiyakittisopon, Kamolpat |
collection | PubMed |
description | BACKGROUND: Uncontrolled hyperphosphatemia in chronic kidney disease (CKD) patients commonly results in vascular calcification leading to increased risk of cardiovascular disease. Phosphate binders (PBs) are used for hyperphosphatemia and can be calcium-based (CBPBs) or non-calcium-based (NCBPBs), the latter being more expensive than CBPBs. In this study, we used meta-analysis approaches to assess the cost-utility of PBs for hyperphosphatemia in CKD patients. METHODS: Relevant studies published prior to June 2019 were identified from PubMed, Scopus, the Cochrane Library, the National Health Service Economic Evaluation Database, and the Cost-Effectiveness Analysis Registry. Studies were eligible if they included CKD patients with hyperphosphatemia, compared any PBs and reported economic outcomes. Meta-analysis was applied to pool incremental net benefit (INB) across studies stratified by country income. RESULTS: A total of 25 studies encompassing 32 comparisons were eligible. Lanthanum carbonate, a NCBPB, was a more cost-effective option than CBPBs in high-income countries (HICs), with a pooled INB of $3984.4 (599.5–7369.4), especially in pre-dialysis patients and used as a second-line option with INBs of $4860.2 (641.5–9078.8), $4011.0 (533.7–7488.3), respectively. Sevelamer, also a NCBPB, was not more cost-effective as a first-line option compared to CBPBs with a pooled INB of $6045.8 (− 23,453.0 to 35,522.6) and $34,168.9 (− 638.0 to 68,975.7) in HICs and upper middle-income countries, respectively. CONCLUSIONS: Lanthanum carbonate was significantly more cost-effective than CBPBs as a second-line option for hyperphosphatemia in pre-dialysis patients in HICs. However, the use of sevelamer is not more cost-effective as a first-line option compared to CBPBs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-021-01275-3. |
format | Online Article Text |
id | pubmed-8166732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-81667322021-06-03 Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations Chaiyakittisopon, Kamolpat Pattanaprateep, Oraluck Ruenroengbun, Narisa Sapankaew, Tunlanut Ingsathit, Atiporn Mckay, Gareth J. Attia, John Thakkinstian, Ammarin Eur J Health Econ Original Paper BACKGROUND: Uncontrolled hyperphosphatemia in chronic kidney disease (CKD) patients commonly results in vascular calcification leading to increased risk of cardiovascular disease. Phosphate binders (PBs) are used for hyperphosphatemia and can be calcium-based (CBPBs) or non-calcium-based (NCBPBs), the latter being more expensive than CBPBs. In this study, we used meta-analysis approaches to assess the cost-utility of PBs for hyperphosphatemia in CKD patients. METHODS: Relevant studies published prior to June 2019 were identified from PubMed, Scopus, the Cochrane Library, the National Health Service Economic Evaluation Database, and the Cost-Effectiveness Analysis Registry. Studies were eligible if they included CKD patients with hyperphosphatemia, compared any PBs and reported economic outcomes. Meta-analysis was applied to pool incremental net benefit (INB) across studies stratified by country income. RESULTS: A total of 25 studies encompassing 32 comparisons were eligible. Lanthanum carbonate, a NCBPB, was a more cost-effective option than CBPBs in high-income countries (HICs), with a pooled INB of $3984.4 (599.5–7369.4), especially in pre-dialysis patients and used as a second-line option with INBs of $4860.2 (641.5–9078.8), $4011.0 (533.7–7488.3), respectively. Sevelamer, also a NCBPB, was not more cost-effective as a first-line option compared to CBPBs with a pooled INB of $6045.8 (− 23,453.0 to 35,522.6) and $34,168.9 (− 638.0 to 68,975.7) in HICs and upper middle-income countries, respectively. CONCLUSIONS: Lanthanum carbonate was significantly more cost-effective than CBPBs as a second-line option for hyperphosphatemia in pre-dialysis patients in HICs. However, the use of sevelamer is not more cost-effective as a first-line option compared to CBPBs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10198-021-01275-3. Springer Berlin Heidelberg 2021-03-06 2021 /pmc/articles/PMC8166732/ /pubmed/33677736 http://dx.doi.org/10.1007/s10198-021-01275-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Chaiyakittisopon, Kamolpat Pattanaprateep, Oraluck Ruenroengbun, Narisa Sapankaew, Tunlanut Ingsathit, Atiporn Mckay, Gareth J. Attia, John Thakkinstian, Ammarin Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations |
title | Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations |
title_full | Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations |
title_fullStr | Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations |
title_full_unstemmed | Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations |
title_short | Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations |
title_sort | evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166732/ https://www.ncbi.nlm.nih.gov/pubmed/33677736 http://dx.doi.org/10.1007/s10198-021-01275-3 |
work_keys_str_mv | AT chaiyakittisoponkamolpat evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations AT pattanaprateeporaluck evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations AT ruenroengbunnarisa evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations AT sapankaewtunlanut evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations AT ingsathitatiporn evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations AT mckaygarethj evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations AT attiajohn evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations AT thakkinstianammarin evaluationofthecostutilityofphosphatebindersasatreatmentoptionforhyperphosphatemiainchronickidneydiseasepatientsasystematicreviewandmetaanalysisoftheeconomicevaluations |